Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism

[1]  Helmut L. Haas,et al.  Functional diversity of ventral midbrain dopamine and GABAergic neurons , 2004, Molecular Neurobiology.

[2]  D. Perl,et al.  Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.

[3]  S. Mandel,et al.  Early and Late Gene Changes in MPTP Mice Model of Parkinson's Disease Employing cDNA Microarray , 2002, Neurochemical Research.

[4]  T. Svensson,et al.  Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.

[5]  S. Hemby,et al.  Time‐dependent changes in gene expression profiles of midbrain dopamine neurons following haloperidol administration , 2003, Journal of neurochemistry.

[6]  K. O’Malley,et al.  Parkinsonian Mimetics Induce Aspects of Unfolded Protein Response in Death of Dopaminergic Neurons* , 2003, Journal of Biological Chemistry.

[7]  S. Mandel,et al.  Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. , 2003, Trends in pharmacological sciences.

[8]  Patricia Soteropoulos,et al.  EZ-Retrieve: a web-server for batch retrieval of coordinate-specified human DNA sequences and underscoring putative transcription factor-binding sites. , 2002, Nucleic acids research.

[9]  A. Dahlström,et al.  Differential localization of α-, β- and γ-synucleins in the rat CNS , 2002, Neuroscience.

[10]  Ted M. Dawson,et al.  Animal Models of PD Pieces of the Same Puzzle? , 2002, Neuron.

[11]  Abraham Weizman,et al.  Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson’s disease , 2001, Neuroscience Letters.

[12]  G. Zeevalk,et al.  Differential sensitivity of mesencephalic neurons to inhibition of phosphatase 2A. , 2001, The Journal of pharmacology and experimental therapeutics.

[13]  C. Kruse,et al.  In vitro modulation of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area by antipsychotic drugs , 2001, Neuropharmacology.

[14]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Nuttall,et al.  An evaluation of the performance of cDNA microarrays for detecting changes in global mRNA expression. , 2001, Nucleic acids research.

[16]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Housman,et al.  Functional genomics reveals a family of eukaryotic oxidation protection genes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[19]  M. Massi,et al.  The psychopharmacology of tachykinin NK-3 receptors in laboratory animals , 2000, Peptides.

[20]  D. Aunis,et al.  Immunohistochemical studies of the localization of neurons containing the enzyme that synthesizes dopamine, GABA, or γ‐hydroxybutyrate in the rat substantia nigra and striatum , 2000, The Journal of comparative neurology.

[21]  S. Kubo,et al.  Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. , 2000, Parkinsonism & related disorders.

[22]  L. Liotta,et al.  IF-LCM: laser capture microdissection of immunofluorescently defined cells for mRNA analysis rapid communication. , 2000, Kidney international.

[23]  R R Maronpot,et al.  Effects of fixation on RNA extraction and amplification from laser capture microdissected tissue , 1999, Molecular carcinogenesis.

[24]  M. Jackson,et al.  Gene expression profiles of laser-captured adjacent neuronal subtypes , 1999, Nature Medicine.

[25]  V. L. Thompson,et al.  Synaptic activity-dependent modulation of mitochondrial gene expression in the rat hippocampus. , 1998, Brain research. Molecular brain research.

[26]  O. Hornykiewicz,et al.  Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.

[27]  T. Heinemeyer,et al.  Databases on transcriptional regulation : TRANSFAC , TRRD and COMPEL , 1997 .

[28]  W. Silverman,et al.  Calcium-binding proteins in the substantia nigra and ventral tegmental area during development: correlation with dopaminergic compartmentalization. , 1997, Brain research. Developmental brain research.

[29]  D. German,et al.  Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[30]  L. Liotta,et al.  Laser Capture Microdissection , 1996, Science.

[31]  K. Tipton,et al.  Nature of Inhibition of Mitochondrial Respiratory Complex I by 6‐Hydroxydopamine , 1996, Journal of neurochemistry.

[32]  I-Hsien Wu,et al.  Stress-induced binding of the transcriptional factor CHOP to a novel DNA control element , 1996, Molecular and cellular biology.

[33]  C. Yokoyama,et al.  Lateromedial Gradient of the Susceptibility of Midbrain Dopaminergic Neurons to Neonatal 6-Hydroxydopamine Toxicity , 1995, Experimental Neurology.

[34]  Y. Hurd,et al.  The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons , 1994, Neuroscience.

[35]  D. Riche,et al.  Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in parkinson's disease , 1994, Neuroscience.

[36]  J. Greenamyre,et al.  Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[37]  C. Gall,et al.  Dopaminergic neurons in rat ventral midbrain express brain‐derived neurotrophic factor and neurotrophin‐3 mRNAs , 1994, The Journal of comparative neurology.

[38]  Y. Agid,et al.  Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. , 1994, Brain research. Molecular brain research.

[39]  J. Rinne.  Nigral degeneration in parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[40]  D. Sulzer,et al.  Identified postnatal mesolimbic dopamine neurons in culture: morphology and electrophysiology , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[41]  S. Nakanishi,et al.  Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: An in situ hybridization study in adult and developing rat , 1992, The Journal of comparative neurology.

[42]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[43]  I. Torres-Aleman,et al.  Localization of insulin-like growth factor I (IGF-I)-like immunoreactivity in the developing and adult rat brain , 1991, Brain Research.

[44]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[45]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[46]  A. Graybiel,et al.  Patterns of cell and fiber vulnerability in the mesostriatal system of the mutant mouse weaver. I. Gradients and compartments , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[48]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[49]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[50]  C. Markham,et al.  Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP , 1987, Brain Research.

[51]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[52]  A. Graybiel,et al.  Weaver mutation has differential effects on the dopamine-containing innervation of the limbic and nonlimbic striatum , 1984, Nature.

[53]  Diana Brahams,et al.  Medicine and the Law , 1983, The Lancet.